VENTYX BIOSCIENCES, INC.

VENTYX BIOSCIENCES, INC.

A biotechnology company focused on developing innovative treatments for a range of rare and ultra-rare diseases.

Stock Performance Snapshot

Buy

Analyst Rating

Analysts recommend buying Ventyx's stock with a target price of $12, indicating strong growth potential.

Above Average

Financial Health

Ventyx is showing strong cash flow and book value, indicating good financial stability.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Baskets Featuring VTYX

Pharma M&A Targets: Biotech Stocks to Watch 2025

Pharma M&A Targets: Biotech Stocks to Watch 2025

AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.

Published: October 5, 2025

Explore Basket
Lottery Tickets

Lottery Tickets

These visionary companies are betting it all on game-changing innovations that could revolutionize entire industries. Hand-selected by our analysts, each represents a high-risk, high-reward opportunity with potential for explosive growth if their breakthrough technologies succeed.

Published: June 17, 2025

Explore Basket

Why You’ll Want to Watch This Stock

📈

Small‑cap dynamics

Market moves can be large and rapid for a ~$268m company, offering potential upside but also heightened volatility and liquidity risk.

🌍

Pipeline & trials

Clinical progress and regulatory news typically drive value. Check trial phases and read peer comparisons, though outcomes can be binary.

Funding considerations

R&D costs may require future capital raises, which can dilute shareholders; assess cash runway and management funding plans.

Why invest with Nemo?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

VRTX

Vertex Pharmaceuticals Incorporated

Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.

REGN

Regeneron Pharmaceuticals, Inc.

Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.

ALNY

Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).

Frequently asked questions